In brief
In a bold move to pressure Denmark for Greenland's sovereignty, President-elect Trump has threatened high tariffs, sparking potential concerns as Denmark is a key supplier of popular American goods, particularly in pharmaceuticals.
President-elect Donald J. Trump's recent commentary on imposing high tariffs on Denmark if the country does not cede Greenland to the United States has raised eyebrows not just in international relations, but for potential consequences on American consumers. Denmark, albeit a small trading partner, is known for exporting vital goods to the U.S. market, particularly in the pharmaceutical sector.Arguing that Greenland is essential for national security, Trump highlighted a willingness to engage in economic pressure. While Denmark exported more than $11 billion in goods to the United States in 2023, its exports to the U.S. include a significant portion of pharmaceuticals, which could face increased prices if tariffs are enacted. As noted by the Observatory of Economic Complexity, about half of Denmark’s exports to the U.S. consist of medicines, including crucial products manufactured by the pharmaceutical giant Novo Nordisk.Novo Nordisk is particularly known for its popular weight-loss drugs, Ozempic and Wegovy, which have become staples in American healthcare. This helps illustrate how intertwined U.S. health interests are with products from Denmark, emphasizing worries about accessibility and pricing should tariffs take effect. The company’s spokesperson acknowledged awareness of the situation but refrained from commenting on any hypothetical outcomes. As the political climate evolves, the effects of Trump's tariff threats could extend far beyond international relations, potentially jeopardizing the availability and affordability of key medical products that countless Americans depend on.

